Compare Ascendis Pharma A/S (ASND) vs FuelCell Energy Inc (FCEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs FuelCell Energy Inc — how do they compare? Ascendis Pharma A/S trades at $254.44 (market cap $16.67B), while FuelCell Energy Inc trades at $22.31 (market cap $1.54B). The key difference: Ascendis Pharma A/S is far larger — about 10.8× FuelCell Energy Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, FuelCell Energy Inc nearer its low. Which is the better fit depends on your goals.
| ASND | FCEL | |
|---|---|---|
Market Cap | $16.67B | $1.54B |
Sector | Health | Industrials |
52-Week High | $277.18 | $36.01 |
52-Week Low | $189.74 | $3.92 |
Enterprise Value | $17.04B | $1.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.17, down slightly by 0.18% on the day, while maintaining strong analyst support with 92% buy ratings and a $309.75 consensus price target. The company shows impressive revenue growth from $51M in 2022 to $720M in 2025, with profitability improving as net loss narrows to -$228M. Recent technical indicators show a bullish trend with the stock trading near resistance at $255-257, while fundamental metrics reveal high valuation ratios (P/E 29.05, P/S 15.68) offset by exceptional gross margins of 89.04%.
ASND presents a compelling growth story with multiple product launches in rare endocrine diseases driving revenue expansion, though investors face risks from negative shareholder equity and high debt levels. The company's transition to positive operating cash flow ($54M in 2025) and inclusion in Russell indexes signal maturation, but execution risks remain as the stock trades at premium valuations requiring continued strong performance to justify current levels.
FCEL trades at $21.32, up 7.51% in the last 24 hours, with a bearish technical signal and RSI near oversold levels. The company reported a net loss of $187.9 million in 2025, with negative gross and net income margins, though revenue grew to $158.16 million. Recent news highlights partnerships with Siemens and focus on AI-driven power demand, but cash flow from operations remains negative.
The outlook is mixed: analyst consensus is split between Buy and Hold with a $20.75 price target, slightly below current price. Key risks include persistent losses, high cash burn, and competitive pressures in the hydrogen sector. Upside potential hinges on execution of growth initiatives and profitability improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →
